Olema partners with Bayer for OP-3136 + darolutamide Phase 1b/2 in mCRPC; 36 patients, H2 2026 start

Olema Pharmaceuticals, Inc.

Olema and Bayer will evaluate OP-3136 (KAT6 inhibitor) combined with darolutamide in ~36 mCRPC patients.
Phase 1b/2 study expected to initiate in second half of 2026; Bayer supplies darolutamide.
Olema retains full global commercial and marketing rights to OP-3136; clinical data and inventions jointly owned.
First clinical collaboration for OP-3136; builds on ongoing Phase 1/2 monotherapy and combination studies.
Olema to present initial Phase 1 OP-3136 monotherapy data at ASCO on May 30, 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.